Why Neurocrine Paid $2.9B for Soleno

Neurocrine Biosciences acquired Soleno Therapeutics for $2.9B, adding rare disease drug Vykat in a deal signaling strong biotech M&A momentum

11 Jun 2026

Somewhere in the calculus of modern drug dealmaking, certainty has acquired a precise price: $53 per share, or about $2.9bn. That is what Neurocrine Biosciences paid on April 6th to acquire Soleno Therapeutics, a company whose chief asset is Vykat, a treatment for the compulsive hunger associated with Prader-Willi syndrome. The 34% premium Neurocrine offered reflects not optimism about future science but relief about past regulatory decisions.

Vykat won approval from the Food and Drug Administration in March 2025. By the time Neurocrine came calling, Soleno had done the hard part. Years of clinical development, regulatory engagement, and investor patience had produced something rare in biotechnology: a commercially viable drug with no approval risk attached. For a larger company watching its existing portfolio age toward patent expiry, that kind of certainty is worth paying for.

Prader-Willi syndrome is a genetic disorder that leaves patients with a persistent, often dangerous sense of hunger. Until Vykat, treatment options were limited. Neurocrine, with its established commercial infrastructure, is better placed than a small biotech to reach patients quickly and at scale.

The broader context matters here. Patent cliffs loom over many large biotechs, and the pipeline of genuinely novel drugs remains unpredictable. Buying approved drugs, even at a premium, offers a more legible path to revenue than early-stage bets. Analysts who follow the orphan disease sector expect similar transactions throughout 2026, as acquirers pursue approved therapies in areas where regulatory pathways are clear and unmet need remains high.

Whether patients benefit as quickly as Neurocrine's press releases imply is another question. Larger organizations bring resources, but they also bring complexity. The commercialisation of rare disease therapies depends as much on patient identification, specialist education, and payer negotiations as on funding. Soleno's investors have been rewarded handsomely. Whether the patients Vykat was designed to help will feel the same is a slower story, and a less certain one.